For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The FDA throws out the company’s second attempt at an accelerated approval.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
